Study: Selumetinib promotes radioiodine absorption in thyroid cancer

02/13/2013 | MedPage Today (free registration)

A new kinase inhibitor called selumetinib made advanced thyroid cancer more susceptible to radioiodine, especially in patients with RAS mutations in their disease, according to a study published in the New England Journal of Medicine. The drug restored or increased the absorption of iodine in 12 of 20 patients who were previously resistant to radioiodine, according to findings on PET images. "These results provide a proof of principle that MEK inhibitors can induce iodine uptake and retention in thyroid tumors," researchers said.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD